

Haematologica
HAEMATOL/2018/205229
Version 3

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma:
extended 3.5-year follow-up from a pooled analysis

Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer,
Brad Kahl, José-Ángel Hernández-Rivas, Keqin Qi, Sanjay Deshpande,
Lori Parisi, and Michael Wang

Disclosures: S. Rule has been a consultant for Janssen, Roche, Astra-Zeneca, Celgene, Pharmacyclics, Gilead, Sunesis, TG Therapeutics, Napp, and Kite, has received honoraria from Janssen, Roche, Astra-Zeneca, Celgene, Pharmacyclics, Gilead, Sunesis, and TG Therapeutics, and has received research funding from Janssen and Roche. M. Dreyling has been a member of the board of directors or advisory committees for Roche, has been a consultant and on speakers' bureaus for Roche, Bayer, Celgene, Gilead, and Janssen, has been a consultant for Mundipharma, Sandoz, and MorphoSys AG, and has received honoraria from Roche and research funding from Roche, Celgene, Janssen, and Mundipharma. A. Goy has no conflicts of interest to disclose. G. Hess has received research funding from Roche, Pfizer, CTI, and Celgene and personal fees from Roche, Pfizer, Janssen, and Celgene. R. Auer has received personal fees from Janssen, Bristol-Myers Squibb, and Celgene. B. Kahl has received research funding from Pharmacyclics and personal fees from Pharmacyclics, Gilead, and Infinity. J. Á. Hernández-Rivas has received honoraria from and served as an advisor for Janssen, Celgene, Roche, Takeda, Amgen, AbbVie, and Gilead. K. Qi, S. Deshpande, and L. Parisi are Janssen employees. M. Wang has been a consultant for Janssen, Pharmacyclics, and Acerta Pharma, has received honoraria from Janssen, Pharmacyclics, Acerta Pharma, and Celgene, and has received research funding from Janssen, Pharmacyclics, Acerta Pharma, Celgene, Karus, Asana, Kite Pharma, Juno Therapeutic, BeiGene, Oncternal, Oncoceutics, Novartis, and Karyopharm. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinical-trials/transparency>. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at <http://yoda.yale.edu>.

Contributions: All authors conceived and/or designed the work that led to this submission, acquired data and/or played an important role in interpreting the results. All authors were involved in drafting or reviewing the manuscript, and all authors approved the final version of the manuscript.